Clinical trials: Tissue Ischemia
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually…
- Trial name
- RE-WARM (NCT07748000)
- Testing
- LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm
- Volunteers
- 75 people
- Sponsor
- Liquidia Technologies, Inc.
Stroke, Brain Infarction
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a full dose of IV recombinant tissue plasminogen activator (rt-PA) plus IV eptifibatide started within 3 hours of symptom onset…
- Trial name
- CLEAR-FDR (NCT01977456)
- Testing
- Eptifibatide
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Arthur Pancioli
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Septic Shock, Sepsis
Vasopressor Use Improves Macrocirculation, But What Are Its Effects on Microcirculation?
To manage the treatment in the intensive care unit for patients with septic shock, central venous oxygen saturation (scvO2) is used as a macrocirculatory indicator, with a target value of 70% or higher being recommended.
- Conditions
- Septic Shock, Sepsis, Tissue Ischemia, Hemodynamic Instability
- Trial name
- NCT07312071
- Testing
- Vascular Occlusion Test
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Stroke
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
- Trial name
- CHABLIS-T II (NCT04516993)
- Testing
- Tenecteplase, The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Huashan Hospital
Slow Coronary Flow, Normal, or Near Normal Coronary Angiography
Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow coronary flow is an angiographically diagnosed phenomenon defined as delayed opacification of epicardial arteries in the absence of significant arterial narrowing and blockade.
- Conditions
- Slow Coronary Flow, Normal, or Near Normal Coronary Angiography, Stable Angina
- Trial name
- NCT02254252
- Testing
- Nicorandil, Nitroglycerin
- Volunteers
- 54 people
- Sponsor
- Mashhad University of Medical Sciences
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Critical Limb Ischemia
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia
The purpose of this study is to evaluate the safety and efficacy of the concentrated autologous bone marrow derived stem cells for the treatment of Critical Limb Ischemia patients.
- Trial name
- NCT01472289
- Testing
- Autologous Bone Marrow Mononuclear cells (BMMNCs)
- Where
- India
- Volunteers
- 17 people
- Sponsor
- TotipotentSC Scientific Product Pvt. Ltd.
Walking, Cognitive Function
Transcranial and Rapid Magnetic Stimulation for Gait Apraxia Due to Normal Pressure Hydrocephalus and Cerebral Ischemia
The investigator(neurologist) has published a study in International Congress Series, in the 15th International Conference of Biomagnetism Vancouver Proceedings 2006,and Science Direct website, of 15 patients with brain ischemia…
- Trial name
- NCT00494689
- Where
- 2 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- Devathasan Neurology Practice Pte Ltd
Stroke
Interventional Management of Stroke (IMS) III Trial
The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.
- Trial name
- IMSIII (NCT00359424)
- Testing
- IV rt-PA alone, endovascular therapy
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 656 people
- Sponsor
- Joseph Broderick
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Pressure Ulcer, Incontinence-associated Dermatitis
Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis
This study aims to identify differences and similarities between superficial pressure ulcers (category II and III) and incontinence-associated dermatitis (category IIA) at tissue level.
- Conditions
- Pressure Ulcer, Incontinence-associated Dermatitis, Irritant Contact Dermatitis, Diaper Rash
- Trial name
- NCT03685929
- Testing
- Punch skin biopsy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Ghent
Hypoxia-Ischemia, Brain, Ischemia, Vertebral Artery
Oxygen Concentration and Recovery After Carotid Endarterectomy
This study evaluates effects of high inspiratory oxygen on cerebral tissue oxygenation and patient recovery after carotid endarterectomy.
- Conditions
- Hypoxia-Ischemia, Brain, Ischemia, Vertebral Artery, Artery Stenosis, Carotid
- Trial name
- NCT02991976
- Testing
- Oxygen concentration
- Where
- Croatia
- Volunteers
- 80 people
- Sponsor
- Osijek University Hospital
Ischemic Heart Failure
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration.
- Trial name
- NCT01709279
- Testing
- adipose tissue derived stromal cells dosage
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Kanazawa University
Healthy, Coronary Artery Disease
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
- Trial name
- NCT00584818
- Testing
- PB127 for Injectable Suspension
- Where
- 16 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Ischemic Stroke
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
This study is a prospective trial wherein each included subject will receive the experimental magnetically enhanced diffusion therapy.
- Trial name
- NCT01519076
- Testing
- Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Pulse Therapeutics
Coronary Artery Disease, Atrial Fibrillation
The Genomic Medicine at VA Study
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus…
- Conditions
- Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer
- Trial name
- GenoVA (NCT04331535)
- Testing
- Polygenic risk score (PRS)
- Where
- United States
- Volunteers
- 1,071 people
- Sponsor
- Boston VA Research Institute, Inc.
Psoriasis, Vascular Inflammation
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.
- Conditions
- Psoriasis, Vascular Inflammation, Coronary Atherosclerosis
- Trial name
- NCT01722214
- Testing
- Adalimumab
- Where
- 5 sites in Canada
- Volunteers
- 107 people
- Sponsor
- Innovaderm Research Inc.
Normal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease
3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
The investigators seek to test bolus infusions (50ml/min) vs. slow infusions (20 ml/min) of Rb-82 on metrics of coronary blood flow assessed on a modern 3D PET/CT.
- Conditions
- Normal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease, Cardiac Risk Factors, Myocardial Infarction
- Trial name
- NCT05286593
- Testing
- Slow Infusion of Rubidium-82
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Ochsner Health System